Compare ARK Genomic Revolution ETF (ARKG) vs Diageo plc (DEO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Diageo plc — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while Diageo plc trades at $81.81 (market cap $44.73B). The key difference: Diageo plc pays a 4.05% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Diageo plc nearer its low. Which is the better fit depends on your goals.
| ARKG | DEO | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $115.33 |
52-Week Low | $23.09 | $72.47 |
Market Cap | — | $44.73B |
Enterprise Value | — | $65.55B |
Dividend Yield | — | 4.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Diageo (DEO) trades at $82.03, up 1.76% with bearish technical signals but mixed fundamentals. The stock shows strong profitability with 12.19% net margins and 22.29% ROE, though recent earnings were mixed with a Q2 2025 miss. Analyst sentiment leans positive with 49% buy ratings, but technical indicators show 15 sell signals versus 1 buy. Recent news highlights CEO Dave Lewis's upcoming strategy update amid US market challenges and promotional increases to stabilize sales.
The outlook remains cautious due to weak US demand and competitive pressures, but valuation at multi-year lows and cost-saving initiatives offer potential upside. Key risks include execution on the new strategy and consumer spending trends. Investors should weigh the dividend yield and recovery potential against near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Diageo plc
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →
